Clinical trials: Flu
Influenza
Control of Epidemic Influenza Through a School-based Influenza Vaccination Program
The main purpose of this study is to learn if influenza vaccines (live attenuated and inactivated influenza vaccines), when given to school-aged children 4 to 18 years of age, can stop or lessen the influenza (flu) outbreak in…
- Trial name
- CEI (NCT00138294)
- Testing
- live attenuated and inactivated influenza vaccines
- Where
- 2 sites in United States
- Volunteers
- 29,255 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
COVID - 19
Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers
This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration…
- Trial name
- NCT06831786
- Testing
- Bivalent mRNA SARS-CoV-2 vaccine, Quardrivalent influenza vaccine
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Prince of Songkla University
Healthy
Immune and Hormone Response to Influenza Vaccine
The purpose of this pilot research project is to look at the effect of the inactivated influenza vaccine (seasonal flu shot) on early signs of immune or germ-fighting response known as cytokines or signal molecules.
- Trial name
- NCT01978262
- Testing
- Seasonal Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Influenza (Healthy Volunteers)
Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea
To describe the immune response induced by quadrivalent recombinant influenza vaccine (RIV4) and Quadrivalent-inactivated Influenza Vaccine (IIV4) in 18-49 and greater than or equal to (>=) 50 years of age participants by…
- Trial name
- NCT05144945
- Testing
- Quadrivalent Recombinant Influenza Vaccine (RIV4), Quadrivalent inactivated influenza vaccine (IIV4)
- Where
- 3 sites in South Korea
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Avian Influenza, Influenza Immunisation
Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza
This is a randomized, double-blinded, Phase II study in healthy males and non-pregnant females, 18-64 years of age. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of a pre-pandemic 2017…
- Trial name
- NCT03682120
- Testing
- A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent
- Where
- 7 sites in United States
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With Influenza
This research is being done to determine if an extract of cooked elderberries will help decrease the duration and severity of influenza symptoms in patients with confirmed influenza.
- Trial name
- NCT03410862
- Testing
- Elderberry Extract
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- michael macknin
Flu Vaccine
Senescent Immunity in Elders and Vaccine Responses (SILVER)
To study the effects of age on the immune system's response to flu vaccine and to study the connection between the immune system and physical and cognitive changes associated with aging.
- Trial name
- NCT04077424
- Testing
- Fluzone-High Dose Quadrivalent, Fluad, Flublock
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
HIV Infection
Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
The overall goal of this study is to compare the safety and immunogenicity of trivalent Fluzone® High-Dose vaccine vs the regular standard-dose (SD) in HIV infected individuals.
- Trial name
- NCT01262846
- Testing
- Fluzone®
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- University of Pennsylvania
Quality of Life, Injection Site Reaction
Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
This study is a prospective, randomized clinical trial. During this study, participants will be randomly assigned to receive quadrivalent inactivated influenza vaccine (IIV4) and mRNA COVID-19 vaccine either simultaneously or…
- Conditions
- Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
- Trial name
- NCT05028361
- Testing
- mRNA COVID-19, IIV4
- Where
- 3 sites in United States
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Duke University
Influenza, Human
Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years
This randomized, active comparator trial will compare the clinical efficacy of recombinant influenza vaccine (RIV) to standard-dose egg-based inactivated influenza vaccine (SD IIV) among adults aged 18-64 years.
- Trial name
- NCT05514002
- Testing
- Fluzone Quadrivalent, Flublok Quadrivalent
- Where
- 4 sites in United States
- Volunteers
- 3,988 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Prophylaxis of A/H3N2v Influenza
Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.
Evaluate the safety and immunogenicity of three dosage levels of swine influenza vaccine in children ages 3 to <9 years, adolescents 9 to <18 years, adults 18 to <65 years and elderly 65 years and older.
- Trial name
- NCT01855945
- Testing
- Swine Influenza
- Where
- 11 sites in United States
- Volunteers
- 627 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Acute Respiratory Distress Syndrome, Influenza
STIP: Statin Trial for Influenza Patients
To assess the efficacy and safety of oral rosuvastatin in patients with suspected or confirmed influenza who require intensive care unit (ICU) admission due to respiratory distress.
- Conditions
- Acute Respiratory Distress Syndrome, Influenza, H1N1 Influenza
- Trial name
- STIP (NCT00970606)
- Testing
- Rosuvastatin (crestor)
- Where
- 21 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gordon Bernard
SARS-CoV-2 Infection, Influenza A
SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
The Metrix COVID/Flu Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B
- Trial name
- NCT06191393
- Testing
- Aptitude Medical Systems Metrix COVID/Flu Test
- Where
- 3 sites in United States
- Volunteers
- 614 people
- Sponsor
- Aptitude Medical Systems
Influenza
Mechanisms of Severe Acute Influenza Consortium (MOSAIC)
The ultimate goal of this collaborative, intensive study is to discover new and effective treatments and to develop better vaccines that can be used in future outbreaks of Influenza A.
- Trial name
- MOSAIC (NCT00965354)
- Where
- 8 sites in United Kingdom
- Volunteers
- 131 people
- Sponsor
- Imperial College London
Influenza
Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM
The aim of this study is to evaluate the immune response and the safety of one injection of FluarixTM/ Influsplit SSW® 2010/2011 or Pandemrix TM in subjects who had received a single Pandemrix TM dose at least 6 months preceding…
- Trial name
- NCT01160237
- Testing
- PandemrixTM, FluarixTM/ Influsplit SSW® 2010/2011
- Where
- 5 sites in Germany
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012
This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT03022435
- Testing
- TIV, High-Dose TIV, LAIV
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older
This clinical trial aims to study the immunogenicity of GSK Biologicals' influenza vaccine GSK2186877A in people aged 65 years or older.
- Trial name
- NCT00765076
- Testing
- GSK Biologicals' influenza vaccine GSK2186877A, GSK Biologicals' Fluarix
- Where
- 4 sites in United States, Spain
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine
The pivotal Phase 3 trial plans to enroll a total of approximately 12,460 participants aged 50+ over two years. Participants will be immunized twice with the M-001 universal influenza vaccine candidate or placebo and then…
- Trial name
- NCT03450915
- Testing
- M-001, Saline
- Where
- 2 sites in Poland
- Volunteers
- 12,460 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Influenza
Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.
To compare the groups with respect to influenza immune responses following Dose 1 of Fluzone vaccine (2006-2007 formulation).
- Trial name
- NCT00390884
- Testing
- Influenza Virus Vaccine, Fluzone®
- Where
- 5 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM
The purpose of this study is to generate additional data on the immunogenicity and safety of revaccination with Fluzone Intradermal (ID) or Fluzone Intramuscular (IM) vaccine.
- Trial name
- NCT01011049
- Testing
- Influenza Virus Vaccine USP Trivalent Types A and B
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company